InvestorsHub Logo
Followers 64
Posts 6479
Boards Moderated 0
Alias Born 03/17/2017

Re: polarbear77 post# 134089

Wednesday, 12/13/2017 9:57:52 AM

Wednesday, December 13, 2017 9:57:52 AM

Post# of 469927
https://www.moneyshow.com/articles/global-47508/anavex-hope-in-treating-alzheimers/

AVXL IS ridiculously undervalued.
There is no serious shorter or analyst predicting that A273 will not be able to even SOC one of the aimed diseases. If A273 will even succeed in ONE of the many upcoming last phase trials its worth a SP of at least $ 25-30 given present issued share count. And easy within reach within next 9 to 12 months. There are biotechs out there who would dream of the trial position Anavex has and are valued at billions.

The SP beating of the last 6 months would be appropriate for a biotech suffering from a huge trial technical set back. Anavex presented us in Nov that it delivering on its drug promises and gets a beating because of a few months delay. ??

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News